Sarepta Therapeutics is advancing SRP-9003 gene therapy for LGMD, with phase 3 study results expected in early 2025. Learn ...

Clinical development and trial testing of vesleteplirsen (SRP-5051) for Duchenne muscular dystrophy (DMD) was stopped, with ...

Sarepta Therapeutics has an accrual ratio of 0.79 for the year to September 2024. Statistically speaking, that's a real negative for future earnings. To wit, the company did not generate one whit of ...

Fintel reports that on November 7, 2024, Cantor Fitzgerald upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sarepta Therapeutics (SRPT – Research Report) and DocGo (DCGO – Research Report) with bullish sentiments.

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

Uy Ear’s rating is based on several positive developments for Sarepta Therapeutics. The company demonstrated strong financial performance in its third quarter of 2024, with revenues surpassing ...

An FDA expansion of Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) Elevidys has sparked a new surge in sales for the ...

Investors consider Dyne Therapeutics' treatments for muscle diseases and strong cash position as a speculative Buy ...

Sarepta Therapeutics (Nasdaq: SRPT) has announced it will cease development of SRP-5051, an experimental drug for Duchenne ...

Find Therapeutics, TeraImmun, AptaTargets, Trethera, Aditxt, SetPoint Medical, Sarepta Therapeutics, Nucleome Therapeutics, Vaccinex Inc., and others are evaluating new multiple sclerosis drugs to ...

The group was led by Casdin Capital, which surged 16 percent last month, according to an investor. This puts its share class that invests only in public securities up more than 40 percent for the year ...